TP53 and cancer: In order to test whether our observations in HGSOC of co-occurrence of MYC amplification with compensatory survival SCNAs could also be observed in other cancers driven by chromosomal instability40, we compared the genomic landscape of HGSOC (Fig. 4c) to the profile of SCNAs in TP53-mutant triple-negative breast tumours (TCGA cohort, n = 261, Fig. 5a; Metabric cohort, n = 177, Fig. 5b) and squamous lung cancer (TCGA cohort, 501, Fig. 5c).